vTv Therapeutics Inc

vTv Therapeutics Inc. a clinical-stage biopharmaceutical company focuses on the development of orally administered treatments for diabetes. The company's lead drug candidate is TTP399 an orally administered small molecule and liver-selective glucokinase activator for the treatment of type 1 diabetes; and HPP737 an orally administered non-CNS penetrant phosphodiesterase type 4 (PDE4) inhibitor that addresses inflammatory diseases and psoriasis. It is also involved in the clinical development of other programs including TTP273 an oral small molecule GLP-1 receptor agonist for postprandial glucose excursion to treat cystic fibrosis related diabetes; HPP3033 a non-electrophilic therapeutic approach to activating the Nrf2 pathway for the treatment of chronic diseases associated with oxidative stress; azeliragon a RAGE antagonist for inflammatory lung diseases including severe COVID-19 as well as for pancreatic and breast cancers; and HPP971 an Nrf2 activator. vTv Therapeutics Inc. has a license agreement with Reneo Pharmaceuticals Inc. to develop and commercialize peroxisome proliferation activated receptor delta agonist program including the compound HPP593; and license and research agreements with Hangzhou Zhongmei Huadong Pharmaceutical Co. Ltd.; Newsoara Biopharma Co. Ltd.; JDRF International; and Novo Nordisk A/S. The company was incorporated in 2015 and is headquartered in High Point North Carolina. vTv Therapeutics Inc. is a subsidiary of MacAndrews & Forbes Incorporated.